<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332420</url>
  </required_header>
  <id_info>
    <org_study_id>HQH-201705</org_study_id>
    <nct_id>NCT03332420</nct_id>
  </id_info>
  <brief_title>The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome</brief_title>
  <official_title>A Real-world Study to Evaluate the Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Institute of Pediatrics, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qidong Gaitianli Medicines Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multisite, open-label, prospective and registered study designed to evaluate the&#xD;
      efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multisite, open-label, prospective and registered study designed to evaluate the&#xD;
      efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic&#xD;
      syndrome(PNS). The study will be Planned at 1500 participants, and subjects will be on study&#xD;
      for up to one year. Data will be collected by authorized physicians for 48 weeks. all of the&#xD;
      data included demographic characteristics, information about PNS, laboratory tests and&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of positive urine protein test changing to the negative result</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <description>Duration of positive urine protein test changing to the negative result was measured from day 1 until the time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of positive to negative urine protein</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of negative urine protein subjects to the total number of subjects, measured from day 1 until the time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The decrease of 24-hour urine protein level</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>Compared 24-hour urine protein level between baseline and follow-up timepoint, measured from day 1 until time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of blood albumin levels</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>Compared blood albumin levels between baseline and follow-up timepoint, assessed up to 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of PNS</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of recurrent subjects to the total number of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of infectious complications of PNS</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of complicated infectious subjects to the total number of subjects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1507</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Observational 1</arm_group_label>
    <description>Huaiqihuang Granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 2</arm_group_label>
    <description>Standard treatment+Huaiqihuang Granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 3</arm_group_label>
    <description>Standard treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children are diagnosed with primary nephrotic syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In accordance with Pediatric Branch , the Chinese Medical Association in 2009:&#xD;
             guidelines for diagnosis and treatment of common kidney diseases in children (for&#xD;
             trial)Ⅰ. Hormone-sensitive, relapsed/dependent nephrotic syndrome diagnostic and&#xD;
             evidence-based guidelines; Ⅲ.Diagnostic criteria for the diagnostic and evidence-based&#xD;
             guidelines for hormone-resistant nephrotic syndrome, which means children who are&#xD;
             diagnosed with primary nephrotic syndrome should be included;&#xD;
&#xD;
          2. Age from 1 to18;&#xD;
&#xD;
          3. ALT and AST levels do not exceed twice the upper limit of the normal range;;&#xD;
&#xD;
          4. Provision of written informed consent by legal guardians.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. a variety of secondary nephrotic syndromes are caused by infectious diseases such as&#xD;
             lupus nephritis, hepatitis b associated nephritis, purpura nephritis, and EB virus,&#xD;
             cytomegalovirus (CMV), etc;&#xD;
&#xD;
          2. with combined diseases of cardiovascular, liver, hematopoietic system, mental&#xD;
             disorders and other serious diseases;&#xD;
&#xD;
          3. History of diabetes or examinations showed elevated blood glucose levels;&#xD;
&#xD;
          4. Participation in other ongoing clinical trials or during their observation period&#xD;
             within the last three months prior to visit 1;&#xD;
&#xD;
          5. Previous/concomitant treatment with any other immunomodulators within the last three&#xD;
             months prior to visit 1 ;&#xD;
&#xD;
          6. Patients who are unlikely to adhere to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaoying Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of The Capital Institute of Pediatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Capital Institute Of Pediatrics</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Children's Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Weihui</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Children's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benq Medical Center</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Children's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuzhou Children's Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincal Children's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Shanxi</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chengdu Women's and Children's Central Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urumqi first people's Hospital</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Children's Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huaiqihuang granule</keyword>
  <keyword>primary nephrotic syndrome</keyword>
  <keyword>multisite</keyword>
  <keyword>prospective</keyword>
  <keyword>open-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

